Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

26 results about "Schizophrenia" patented technology

A mental disorder characterized by delusions, hallucinations, disorganized speech and behavior.

Schizophrenia early recognition and risk prediction method and system based on multi-mode speech analysis

The invention provides a schizophrenia early recognition and risk prediction method and system based on multi-mode speech analysis, and belongs to the technical field of medical artificial intelligence. The method comprises the following steps: prospectively acquiring natural voice data of an individual in a clinical high-risk period, performing clinical follow-up visit for two years, and constructing a first Chinese schizophrenia clinical high-risk voice longitudinal data set; based on the data set, audio and text features in the voice are extracted, a layered multi-mode integrated model is constructed, semantic coherence and acoustic features are fused, and early prediction of the schizophrenia transformation risk is achieved; through feature importance analysis, key voice marks closely related to negative symptoms, thinking disorder and cognitive impairment are recognized, and non-invasive, accurate and interpretable early recognition is achieved. According to the method, the technical blank of early screening tools for schizophrenia in Chinese context is filled, and the accuracy and stability of early recognition are remarkably improved.
Owner:SHANGHAI MENTAL HEALTH CENT (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENT)

Traditional Chinese medicine formula for treating schizophrenia

The invention provides a traditional Chinese medicine formula for treating schizophrenia, and belongs to the technical field of traditional Chinese medicine, the traditional Chinese medicine formula for treating schizophrenia comprises the following medicinal materials: gypsum, pig iron, amur skullcap root, ossa draconis, callicarpa bodinieri, buffalo horn, coptis root, baical skullcap root, amur corktree bark, turmeric root-tuber, aloe, suberect spatholobus stem, costus root, Chinese angelica, officinal magnolia bark, elephantopus scaber, rhubarb, mirabilite and the like. A decoction method comprises the following steps: firstly decocting part of the medicinal materials for 40 minutes, then adding the rest of the medicinal materials, decocting for 30 minutes, decocting for three times, mixing, and taking in three times, so as to solve the problems of large side effect, strong dependence, slow effect and the like in the existing treatment method. The traditional Chinese medicine composition has the beneficial effects of relieving side effects, reducing dependency and drug resistance, relatively fast effect taking, relatively stable treatment effect, comprehensive conditioning and the like, various medicinal materials are synergistic, and the effects of clearing heat, purging fire, relieving convulsion, soothing the nerves, promoting qi circulation, relieving depression, activating blood, enriching blood and the like are achieved, so that the symptoms of schizophrenia patients are relieved, and the treatment effect is improved.
Owner:SICHUAN SHENQINGTANG HEALTH MANAGEMENT CO LTD

5-HT2A receptor inverse agonist as well as preparation method and application thereof

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.
Owner:LVYE JIAAO PHARM SHIJIAZHUANG CO LTD

Method and device for generating information based on brain image data

The invention provides a method and device for generating information based on brain image data, and the method comprises the steps: carrying out the longitudinal brain image analysis of the brain image data, collected at multiple time points, of a target individual, carrying out regional division on the brain of the target individual at each time point and extracting morphological measurement values of each region based on a longitudinal brain image analysis result and a cortex partition map; based on the brain form norm, the deviation degree of the morphological measurement value of each region of the brain of the target individual at each time point relative to the brain form norm is determined, and the individual brain form deviation vector corresponding to the target individual at each time point is obtained; performing correlation calculation on the individual brain form deviation vector corresponding to the target individual at each time point and the statistical data of the plurality of mental diseases in the whole brain range to obtain cross-disease brain form similarity features; and inputting the cross-disease brain form similarity features into a pre-trained machine learning model, and outputting classification information about whether the target individual is a schizophrenia patient or not, and / or prediction information about clinical indexes.
Owner:BEIJING UNIV OF POSTS & TELECOMM +1

Injectable formulations of multicyclic antidepressants

PendingAU2024410717A1DiseaseSchizo-affective type
The invention relates to a composition comprising a piperazine-benzazepine, a buffer and a surfactant, and uses of such compositions such as treating, preventing, and / or suppressing symptoms of schizophrenia, schizoaffective disorders, and / or Parkinson's disease. The compositions have improved parameters such as a lower variance in pH, improved stability during storage, and lower solubility of piperazine-benzazepines, resulting in piperazine-benzazepine particle formation with improved particle size and particle size distribution. The compositions are useful as therapeutic agent, for instance through parenteral administration to a subject.
Owner:CLOZATHERA BV

5-HT 2A Receptor inverse agonists, processes for their preparation and use

The present invention relates to a novel compound as a 5-HT 2A receptor inverse agonist, a method for preparing the same and a pharmaceutical composition. It also relates to the use of the compound or the pharmaceutical composition in the manufacture of a medicament for treating 5-HT 2A receptor related diseases, including non-motor symptoms of Parkinson's disease: delusions, hallucinations, depression, anxiety, cognitive impairment, sleep disorders; dementia-related psychiatric disorders; major depressive disorder; or negative symptoms of schizophrenia, etc.
Owner:LVYE JIAAO PHARM SHIJIAZHUANG CO LTD

5-HT2A receptor inverse agonist as well as preparation method and application thereof

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.
Owner:LVYE JIAAO PHARM SHIJIAZHUANG CO LTD

5-HT2A receptor inverse agonist as well as preparation method and application thereof

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.
Owner:LVYE JIAAO PHARM SHIJIAZHUANG CO LTD

Delta wave band fractal dimension individual heterogeneity-based schizophrenia typing method

The invention discloses a schizophrenia typing method based on delta wave band fractal dimension individual heterogeneity, and belongs to the technical field of neural information processing and mental disease auxiliary diagnosis. According to the method, firstly, innovation is achieved in the aspect of frequency band specificity analysis, feature extraction can be carried out on the schizophrenia key information processing frequency band, and disease abnormity can be captured more sensitively. And secondly, the site effect of cross-center data acquisition is effectively coordinated by introducing a ComBat method, and the modeling stability and the result reliability are improved. Thirdly, a standardized model is obtained through multi-center large sample training, individualized deviation modeling is further carried out, the abnormal degree of a single patient relative to a healthy group can be accurately described, and the limitation of traditional group mean value comparison is broken through. Afterwards, in combination with a hierarchical heterogeneity analysis method based on discriminant analysis, stage identification and potential subtype division of the disease are realized, so that the method has a refined typing capability.
Owner:UNIV OF ELECTRONICS SCI & TECH OF CHINA

5-HT2A receptor inverse agonist as well as preparation method and application thereof

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.
Owner:LVYE JIAAO PHARM SHIJIAZHUANG CO LTD

Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia.

UndeterminedPK201200393A0SchizophreniaPharmacology
Owner:H LUNDBECK AS

A sub-millimeter level diffuse magnetic resonance cortical layering cognitive radial index extraction method

This invention discloses a submillimeter-level diffusion magnetic resonance imaging (DTI) method for extracting the radial index of cortical layered cognitive structures, relating to the field of medical image processing technology. This invention aims to address the problems of existing technologies failing to accurately quantify the directionality of cortical microstructures and neglecting the heterogeneity of cortical layering. The method includes: acquiring DTI data and performing high-fidelity preprocessing such as MP-PCA denoising, Gibbs artifact removal, and Gaussian process distortion correction; estimating the diffusion tensor and extracting the principal feature vector based on the preprocessed data; reconstructing the cortical white matter and pia mater surface using T1 images and extracting the normal vector; calculating the absolute value of the dot product of the diffusion principal feature vector and the surface normal vector to construct a radial index map; and segmenting the cortex into multiple intermediate layers based on the principle of equal volume and extracting layering parameters. Through refined high-resolution data processing and geometric modeling, this invention can accurately quantify the radial alignment integrity of cortical nerve fibers, providing highly sensitive imaging markers for cognitive disorders such as schizophrenia.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Method for evaluating recovery benefit of giant panda national park greenway on sperm classification patient

PendingCN121054191AMental therapiesMedical imagesImage QuantificationMedicine
The invention discloses a method for evaluating the recovery benefit of a giant panda national park greenway on a refined patient. The method comprises the following steps: acquiring an image of the giant panda national park greenway; preprocessing the giant panda national park greenway image; selecting a sperm fraction patient subject; obtaining the recovery benefit of the perceptual classification patient subject on the greenway image of the giant panda national park by adopting a perceptual recovery scale; screening environmental factors in the giant panda national park greenway image; quantifying environmental factors in the giant panda national park greenway image; and constructing a correlation prediction model between the environment characteristic factors and the scores of the perception recovery scale. According to the method, environment feature factors are quantified through images, greenway environment features are systematically analyzed, the association prediction model is constructed, dynamic association between environment elements and rehabilitation indexes of the precisely-classified patient is revealed, and a new data-driven normal form is provided for scientific design of the rehabilitation-oriented greenway.
Owner:SICHUAN AGRI UNIV

Construction method and system of schizophrenia symptom severity prediction model

PendingCN121789956AAccurate assessment basisAuxiliary diagnosisMedical automated diagnosisDiseaseAlgorithm
The invention discloses a method and system for constructing a schizophrenia symptom severity prediction model, and relates to the field of disease auxiliary diagnosis, and the method comprises the steps: obtaining historical electroencephalogram data of a patient, and constructing a weighted undirected connection matrix; obtaining a plurality of key graph theory indexes based on the weighted undirected connection matrix in combination with a graph theory algorithm; wherein the plurality of key graph theory indexes comprise a clustering coefficient, a path length, global efficiency and local efficiency; taking the plurality of obtained key graph theory indexes as predictive factors, and inputting the predictive factors and the dependent variable PANSS score into a constructed multiple linear regression model to determine a linear relationship between the plurality of key graph theory indexes and the dependent variable PANSS score; and obtaining a schizophrenia symptom severity prediction model for predicting the symptom severity of the schizophrenia patient according to the linear relationship between the plurality of key graph theory indexes and the PANSS score.
Owner:XINXIANG MEDICAL UNIV

Method of investigating brain aging trajectory deviations in different brain regions of individuals with schizophrenia and brain-age prediction using same

A method of predicting brain age for a subject having a mental health condition. The method comprises obtaining at least one medical image of a brain of a subject; preprocessing the medical image to produce a brain map; segmenting the brain map into more than one brain regions; and calculating a brain age of the subject based on a predetermined set of key features for each of the brain regions.
Owner:NAT YANG MING CHIAO TUNG UNIV +1

Method and system for evaluating cognitive function of mental disorders based on attention mechanism

PendingCN122624073ATime–frequency analysisSchizophrenia
This invention discloses a method and system for assessing cognitive function in mental disorders based on attention mechanisms, belonging to the field of mental disorder assessment technology. The method includes: acquiring multi-channel EEG signals of subjects under an adaptive dual-task paradigm; performing time-frequency analysis to extract frequency bands and instantaneous power time-series features of the frequency bands; inputting the features into a pre-trained game-theoretic attention network to calculate the dynamic game-theoretic coupling strength between the network and oscillations, generating a game equilibrium deviation time-series sequence; extracting an imbalance threshold index and a compensation cost index from the sequence; and inputting the index into a classifier to generate a cognitive function assessment index. This invention analyzes the dynamic game-theoretic relationship between oscillations through attention mechanisms, quantifying the degree of imbalance in attention resource allocation in multi-task competitive scenarios for patients with schizophrenia. It exhibits high sensitivity and specificity, providing an objective and quantitative tool for assessing cognitive impairment in mental disorders.
Owner:SOUTHWEST MEDICAL UNIV

New uses of a 5-HT4 receptor agonist

The present invention relates to new uses of a 5-HT4 receptor agonist, specifically Isopropyl-3 - { 5- [ 1 -(3 - methoxypropyl) piperidin-4-yl] - [ 1,3,4] oxadiazol-2-yl } - 1 H- indazole (Compound- 1) or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment and behavioural and psychological symptoms of dementia such as apathy / indifference, agitation, aggression, depression, anxiety, irritability / lability, dysphoria, aberrant motor behaviour, delusions, hallucinations, elation / euphoria, psychosis, disinhibition, sleep and night time behaviour disorders or appetite and eating disorders. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.
Owner:SUVEN LIFE SCI LTD

Cariprazine orally disintegrating film compositions, methods of making and use thereof

The application provides a cariprazine orally dissolving film composition, a preparation method and application thereof. The orally dissolving film composition comprises an active ingredient, a film forming material and a plasticizer, wherein the active ingredient is selected from a mixture of one or more of cariprazine, a pharmaceutically acceptable salt of cariprazine and an inclusion compound thereof. The orally dissolving film composition has the advantages of thin thickness, good taste, stable property, instant dissolving in the oral cavity without drinking water, fast oral absorption speed, simple process, high drug loading, good drug content uniformity, and the like. The orally dissolving film composition helps to improve the poor compliance, hiding and spitting of patients with schizophrenia, and is particularly suitable for patients with difficulty in swallowing, and has a good market prospect.
Owner:SHANGHAI BOCIMED PHARMA CO LTD

Method of investigating brain aging trajectory deviations in different brain regions of individuals with schizophrenia and brain-age prediction using same

A method of predicting brain age for a subject having a mental health condition. The method comprises obtaining at least one medical image of a brain of a subject; preprocessing the medical image to produce a brain map; segmenting the brain map into more than one brain regions; and calculating a brain age of the subject based on a predetermined set of key features for each of the brain regions.
Owner:NAT YANG MING CHIAO TUNG UNIV +1

LUMATEPERONE FOR USE IN THE TREATMENT OF SCHIZOPHRENIA

ActiveDE602020066329T2Organic active ingredientsOrganic chemistryLumateperoneSchizophrenia
Owner:INTRA CELLULAR THERAPIES INC

Determining subtypes of schizophrenia in a subject, treatment of schizophrenia, medicament for treating schizophrenia and determining the efficacy of such medication

PendingUS20250295322A1Nervous disorderDisease diagnosisManagement of schizophreniaBlood biomarkers
Methods of categorisation of schizophrenia sufferers into subtypes based on changes in brain morphology, together with associated blood biomarkers are provided. The methods allow for more accurate treatment and diagnosis of schizophrenia.
Owner:NAT INST OF MENTAL HEALTH

Formula of traditional Chinese medicinal diet for conditioning and tonifying two different patients with phlegm-fire disturbing type schizophrenia

The invention discloses a traditional Chinese medicinal diet formula for regulating and tonifying two different patients with phlegm-fire disturbing mental schizophrenia, which pays attention to disease source and pathogenesis transformation, compares and distinguishes respective medication safety and effective requirements of the two different patients with phlegm-fire disturbing mental schizophrenia with different constitutions and physiological characteristics, comprehensively applies medicinal and edible homology and prescriptions related theoretical technologies, and has a good curative effect on the patients with phlegm-fire disturbing mental schizophrenia. Various symptomatic medicinal and edible materials for relieving depression and decreasing internal heat, opening orifices, reducing phlegm and eliminating phlegm and reinforcing qi and nourishing vitality are properly integrated, and two safe, cheap and effective medicated food prescriptions are compatible. Relative balance of yin and yang conditioning is the major premise, depression relieving, internal heat decreasing, liver calming and yang suppressing are the fundamental source, phlegm eliminating, mind stabilizing, spleen strengthening, stomach tonifying, qi reinforcing and vitality nourishing are effectively guaranteed, and the three components are organically unified.
Owner:刘小龙

Bifidobacterium animalis subsp. lactis and use thereof

Provided is a Bifidobacterium lactis. The Bifidobacterium lactis is Bifidobacterium animalis subsp. lactis BL-11, and the preservation number of the Bifidobacterium animalis subsp. lactis BL-11 is CGMCC No. 20847. The provided Bifidobacterium animalis subsp. lactis can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit / hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.
Owner:ZHONGKE WISBIOM(BEIJING)BIOTECHNOLOGY CO LTD

A method and device for ADHD case classification based on weighted sum strategy distributed algorithm

The present invention provides an ADHD case classification method and device based on a weighted sum strategy distributed algorithm, and relates to the field of machine learning technology. The present invention uses fMRI data and classification technology, and proposes a distributed multi-objective optimization method based on a weighted strategy, and applies it to a binary ADHD soft margin support vector machine. The multi-objective support vector machine is converted into a single-objective optimization problem using the weighted sum method, and then it is iteratively solved using a distributed method. This method can effectively handle SVMs with multiple performance indicators, improve optimization efficiency through collaboration and coordination between multi-agent systems, and effectively solve the ADHD classification problem with data distributed on different service hosts. Since rs-fMRI shows its unique advantages in the analysis of mental illness, it can be used not only for the classification of ADHD, but also for the classification of schizophrenia and Alzheimer's cases.
Owner:UNIV OF SCI & TECH BEIJING +1